MHLW To Review Shionogi’s Idiopathic Pulmonary Fibrosis Drug
This article was originally published in PharmAsia News
Executive Summary
The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare will review Shionogi's pirfenidone for the treatment of idiopathic pulmonary fibrosis. The Phase III trial conducted this year at Shinagawa Prefecture Cardiovascular and Respiratory Center showed a delay of symptom progression compared to placebo. Designated as an intractable disease in Japan, IPF currently has no thorough treatment. (Click here for more - Japanese language